id: pharmacotherapy_access_to_treatment_retention
name: Access to Evidence-Based Pharmacotherapy for Alcohol Use Disorder â†’ Treatment
  Retention and Safety
from_node:
  node_id: pharmacotherapy_access
  node_name: Access to Evidence-Based Pharmacotherapy for Alcohol Use Disorder
to_node:
  node_id: treatment_retention
  node_name: Treatment Retention and Safety
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Both topiramate and naltrexone demonstrate acceptable safety profiles with
  low withdrawal rates'
- 'Step 2: Topiramate: 8% withdrawal due to side effects; Naltrexone: 5% withdrawal
  due to side effects'
- 'Step 3: Tolerable medication regimens allow patients to remain in treatment over
  12-week period'
- 'Step 4: Sustained engagement with pharmacotherapy enables medication effects to
  reduce drinking and support recovery'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Kirsten C Morley et al. 2024. "Topiramate Versus Naltrexone for
    Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled
    Trial.." *American Journal of Psychiatry*. https://doi.org/10.1176/appi.ajp.20230666'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.667018'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/pharmacotherapy_access_to_treatment_retention.yaml
_category: healthcare_access
